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Superior dialytic clearance of
b2 microglobulin and p-cresol
by high-flux hemodialysis as
compared to peritoneal dialysis
Kidney International (2007) 71, 467. doi:10.1038/sj.ki.5002063
To the Editor: Evenepoel P et al.1 compared the clearance of
b2 microglobulin (b2M) by hemodialysis and peritoneal
dialysis (PD).
Previously, it was postulated that clearance of middle
molecule b2M was greater with PD, as compared to
hemodialysis. However, with introduction of high perfor-
mance dialysis membrane, hemodialysis now appears to be
superior in this aspect. Hereby, we examined the ways in
which decreasing residual renal function had an effect on
serum b2M levels in patients on PD. Associations of b2M
clearance by PD and residual renal function, and serum b2M
levels with duration of dialysis were investigated in 20
subjects on continuous ambulatory PD. The results showed
that serum b2M levels increased with duration of dialysis. As
for b2M clearance by residual renal function per se, it was
significantly lower in subjects with long duration of dialysis
even though no difference was observed in the daily b2M
clearance by PD (Figure 1).
Dialysis adequacy had traditionally been determined by Kt/
V, urinary nitrogen.2 However, in HEMO study, it became
apparent that serum b2M levels, not Kt/V were the strong
predictors of mortality.3 There have been reported that
mortality is lower for PD, as compared to hemodialysis up to
48 months from commencement of PD, provided that there is
residual renal function.4 Although our study only focused on
the changes in serum b2M levels, attempts should be made by
future studies to search for dialysis methods that provide
adequate b2M clearance with a potential decrease in mortality.
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We thank Yoshida et al.1 for their interest in our study
examining the clearance of b2-microglobulin (B2M) and
p-cresol in dialysis patients. The authors report data from
a cross-sectional study on serum levels and clearances of
B2M in 20 patients treated with peritoneal dialysis. Both
parameters showed significant but opposite correlations
with duration of dialysis. This observation is in line with
the results of a recent prospective study in incident
peritoneal dialysis patients.2 In the latter study, serum
levels of B2M were also shown to increase with time on
dialysis. A declining renal clearance, not compensated by
an increased peritoneal clearance emerged as the most
plausible explanation. It is increasingly recognized that
residual renal function is of utmost importance for the
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Figure 1 | Serum b2M levels was increased with duration of
dialysis, urine b2M clearance was decreased and PD b2M
clearance was constant.
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elimination of B2M and protein bound retention solutes.
Given the inferior dialytic clearance of B2M and p-cresol
by peritoneal dialysis as compared to hemodialysis,
patients on peritoneal dialysis are more dependent on
residual renal function at least as far as the removal of
these retention solutes is concerned.3 Very recently, high
serum levels of both solutes were shown to be indepen-
dently associated with increased mortality.4,5 Undoubtedly
these observations will encourage nephrologists to broad-
en their view on adequacy beyond Kt/Vurea. All together,
these data moreover provide additional support for the
integrative care concept.6
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Calcineurin-inhibitors and bone
pain after organ transplantation
Kidney International (2007) 71, 468. doi:10.1038/sj.ki.5002073
To the Editor: Collini et al.1 report two kidney graft
recipients with post-transplant lower limbs transient joint
pain. Bone scintigraphy and magnetic resonance (MR)
imaging of the symptomatic joints showed increased tracer
uptake and bone marrow edema, respectively. As already
suggested by others, they incriminate calcineurin-inhibitors
as the cause of this syndrome.
I do not believe that this hypothesis is warranted. Indeed,
identical symptoms have been described in kidney graft
recipients before the calcineurin-inhibitors era.2 The clinical
presentation best fits with the microtraumatic hypothesis we
initially proposed.3 Indeed, in multiple reports, MR imaging
consistently showed bone marrow edema and/or hemor-
rhage. The demonstration in some patients of bands of
hyposignal within areas of bone marrow edema further
supports the notion of impaction.3 In addition, Yamamoto
et al.4 recently showed in non-transplanted patients that
similar MR imaging lesions of symptomatic areas correspond
histologically to insufficiency fracture. Bone marrow infiltra-
tion with low intensity signal on T1-weighted MR image
corresponds histologically to viable bone and marrow tissue
with associated callus, edema, and vascular granulation.4
More interestingly, the presence in some T1-weighted MR
images of a focal band beneath the articular cartilage
corresponded to a fracture line and its associated repair
tissue.4
I suggest that a microfracture is the cause of this syndrome
and that inadapted physical activity level imposed on a
fragilized post-transplant bone could favor its occurrence.
The onset of the symptoms is thus unlikely to be prevented
by a reduction of calcineurin-inhibitors dose, in contrast to
the authors’ suggestion.
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Dr Goffin makes an interesting objection to the theory of
calcineurin-inhibitor-induced pain syndrome.1 We are
familiar with his hypothesis, which we were unfortunately
unable to deal with due to limits on the length of the paper.
It is true that there is no direct demonstration of the
existence of calcineurin-inhibitor-induced pain syndrome.
The hypothesis of microtraumas occurring in bone already
weakened by steroid therapy at high doses in the
immediate post-transplant period has its validity,2,3 and
it is possible that these repeated microtraumas in such a
delicate period could cause this syndrome. Moreover, this
agrees with the descriptions made before the calcineurin-
inhibitors era,4 with the cases described under therapy
with other types of drugs5 and with the recent comments
by Yamamoto et al.6
But the hypothesis of Grotz et al.7 is equally valid: in the
transplant patients affected by this syndrome there is, in
fact, no demonstration of the ‘insufficiency fractures’
which would be at the base of the alterations which are
found with the magnetic resonance imaging. In addition,
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